186 related articles for article (PubMed ID: 31951166)
1. Carbazole Derivatives as Kinase-Targeting Inhibitors for Cancer Treatment.
Ceramella J; Iacopetta D; Barbarossa A; Caruso A; Grande F; Bonomo MG; Mariconda A; Longo P; Carmela S; Sinicropi MS
Mini Rev Med Chem; 2020; 20(6):444-465. PubMed ID: 31951166
[TBL] [Abstract][Full Text] [Related]
2. Antitumor carbazoles.
Asche C; Demeunynck M
Anticancer Agents Med Chem; 2007 Mar; 7(2):247-67. PubMed ID: 17348830
[TBL] [Abstract][Full Text] [Related]
3. Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitors.
Marminon C; Anizon F; Moreau P; Pfeiffer B; Pierré A; Golsteyn RM; Peixoto P; Hildebrand MP; David-Cordonnier MH; Lozach O; Meijer L; Prudhomme M
Mol Pharmacol; 2008 Dec; 74(6):1620-9. PubMed ID: 18768386
[TBL] [Abstract][Full Text] [Related]
4. Carbazole scaffolds in cancer therapy: a review from 2012 to 2018.
Issa S; Prandina A; Bedel N; Rongved P; Yous S; Le Borgne M; Bouaziz Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1321-1346. PubMed ID: 31328585
[TBL] [Abstract][Full Text] [Related]
5. Benzofuran Small Molecules as Potential Inhibitors of Human Protein Kinases. A Review.
Kwiecień H; Goszczyńska A; Rokosz P
Curr Pharm Des; 2016; 22(7):879-94. PubMed ID: 26648467
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of 5-substituted 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as check point 1 kinase inhibitors.
Sako Y; Ichikawa S; Osada A; Matsuda A
Bioorg Med Chem; 2010 Nov; 18(22):7878-89. PubMed ID: 20943405
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological activities of 4-substituted pyrrolo[2,3-a]carbazole Pim kinase inhibitors.
Giraud F; Akué-Gédu R; Nauton L; Candelon N; Debiton E; Théry V; Anizon F; Moreau P
Eur J Med Chem; 2012 Oct; 56():225-36. PubMed ID: 22982527
[TBL] [Abstract][Full Text] [Related]
8. Promising Targets in Anti-cancer Drug Development: Recent Updates.
Kumar B; Singh S; Skvortsova I; Kumar V
Curr Med Chem; 2017; 24(42):4729-4752. PubMed ID: 28393696
[TBL] [Abstract][Full Text] [Related]
9. Cinnamic Acid Derivatives as Inhibitors of Oncogenic Protein Kinases--Structure, Mechanisms and Biomedical Effects.
Mielecki M; Lesyng B
Curr Med Chem; 2016; 23(10):954-82. PubMed ID: 26980568
[TBL] [Abstract][Full Text] [Related]
10. Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective.
Carlino L; Rastelli G
J Med Chem; 2016 Oct; 59(20):9305-9320. PubMed ID: 27559828
[TBL] [Abstract][Full Text] [Related]
11. Kinase inhibitory potencies and in vitro antiproliferative activities of N-10 substituted pyrrolo[2,3-a]carbazole derivatives.
Akué-Gédu R; Letribot B; Saugues E; Debiton E; Anizon F; Moreau P
Bioorg Med Chem Lett; 2012 Jun; 22(11):3807-9. PubMed ID: 22543026
[TBL] [Abstract][Full Text] [Related]
12. Pyrrolocarbazoles as checkpoint 1 kinase inhibitors.
Hénon H; Conchon E; Hugon B; Messaoudi S; Golsteyn RM; Prudhomme M
Anticancer Agents Med Chem; 2008 Aug; 8(6):577-97. PubMed ID: 18690823
[TBL] [Abstract][Full Text] [Related]
13. Indolinones as promising scaffold as kinase inhibitors: a review.
Prakash CR; Raja S
Mini Rev Med Chem; 2012 Feb; 12(2):98-119. PubMed ID: 22372601
[TBL] [Abstract][Full Text] [Related]
14. The Potential Targets and Mechanisms of a Carbazole and Pyrazole Containing Anticancer Compound.
Xie J; Gore JC
Curr Cancer Drug Targets; 2020; 20(5):364-371. PubMed ID: 31951182
[TBL] [Abstract][Full Text] [Related]
15. New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin.
Moreau P; Dezhenkova LG; Anizon F; Nauton L; Thery V; Liang S; Kaluzhny DN; Shtil AA
Anticancer Agents Med Chem; 2014; 14(9):1228-36. PubMed ID: 25175798
[TBL] [Abstract][Full Text] [Related]
16. Current perspective of natural alkaloid carbazole and its derivatives as antitumor agents.
Shaikh MS; Karpoormath R; Thapliyal N; Rane RA; Palkar MB; Faya AM; Patel HM; Alwan WS; Jain K; Hampannavar GA
Anticancer Agents Med Chem; 2015; 15(8):1049-65. PubMed ID: 25584693
[TBL] [Abstract][Full Text] [Related]
17. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Fabbro D; Ruetz S; Buchdunger E; Cowan-Jacob SW; Fendrich G; Liebetanz J; Mestan J; O'Reilly T; Traxler P; Chaudhuri B; Fretz H; Zimmermann J; Meyer T; Caravatti G; Furet P; Manley PW
Pharmacol Ther; 2002; 93(2-3):79-98. PubMed ID: 12191602
[TBL] [Abstract][Full Text] [Related]
18. Small molecule kinase inhibitors as anti-cancer therapeutics.
Chahrour O; Cairns D; Omran Z
Mini Rev Med Chem; 2012 May; 12(5):399-411. PubMed ID: 22303944
[TBL] [Abstract][Full Text] [Related]
19. Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy.
Soltan OM; Shoman ME; Abdel-Aziz SA; Narumi A; Konno H; Abdel-Aziz M
Eur J Med Chem; 2021 Dec; 225():113768. PubMed ID: 34450497
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
